Nuvectis Pharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Nuvectis Pharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.46M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.33M) | Aug 5, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($6.33M) | Nov 4, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($5.33M) | Nov 4, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($5.33M) | May 6, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($5.33M) | Aug 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.15M) | Nov 4, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($4.43M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.43M) | Aug 5, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($4.17M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.17M) | May 6, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($4.17M) | Nov 4, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.88M) | Nov 5, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.71M) | Aug 6, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($5.71M) | Nov 5, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.05M) | May 7, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($4.05M) | Nov 5, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($4.05M) | Aug 6, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($5.88M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.57M) | Aug 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.79M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.60M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($5.57M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.36M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.64M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.40M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($6.16M) | Nov 5, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.77M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.10M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($5.94M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.57M) | Aug 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($2.95M) | May 10, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($4.67M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.94M) | Aug 10, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($23.0K) | May 12, 2022 |